Search details
1.
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors.
Future Oncol
; 19(2): 123-135, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36877099
2.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37306090
3.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36656302
4.
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.
Future Oncol
; 15(26): 3003-3014, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31339357
5.
Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.
J Bras Pneumol
; 47(4): e20200584, 2021.
Article
in English, Portuguese
| MEDLINE | ID: mdl-34259745
6.
Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
Semin Thorac Cardiovasc Surg
; 29(2): 233-241, 2017.
Article
in English
| MEDLINE | ID: mdl-28823336
7.
Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study / Avaliação prospectiva de espécimes obtidos por meio de EBUS-TBNA quanto à expressão de programmed death-ligand 1 em pacientes com câncer pulmonar de células não pequenas: um estudo piloto
J. bras. pneumol
; 47(4): e20200584, 2021. tab, graf
Article
in English
| LILACS | ID: biblio-1279298
8.
The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.
Immunotherapy
; 10(12): 1041-1045, 2018 09.
Article
in English
| MEDLINE | ID: mdl-30185137
Results
1 -
8
de 8
1
Next >
>>